



Supplementary material

The supplementary material was provided by the authors and some information may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by the Hong Kong College of Radiologists. The Hong Kong College of Radiologists disclaims all liability and responsibility arising from any reliance placed on the content.

Supplement to: Du Q, Kam TY, Yeung MW. Clinical implications of Erb-B2 receptor tyrosine kinase 2 S310 mutations in non–small-cell lung cancer: two case reports. Hong Kong J Radiol. 2024;27:Epub 3 Dec 2024. <https://doi.org/10.12809/hkjr2417806>.

Supplementary Table. Review of Case 1 and Case 2.

	Age/Sex	Smoking status	Medical history	Histology	Molecular test result	Summary of systemic treatment	Outcome
Case 1	65/Male	Non-smoker	<p>1. Intrahepatic cholangiocarcinoma, pT1 cN0M0, R0 liver resection in February 2020</p> <p>2. Right upper lobe lung adenocarcinoma, cT1bN0M0, SBRT 55 Gy/5fr in February 2020. Follow-up CT in January 2022 showed remission in both diseases</p> <p>3. Chronic hepatitis B on entecavir</p>	Adenocarcinoma	1. Tissue NGS at diagnosis: ERBB2 S310F	<p>1st-line: Pemetrexed/carboplatin/pembrolizumab for six cycles, followed by maintenance pemetrexed/pembrolizumab for three cycles</p> <p>2nd-line: T-DXd for four cycles</p> <p>3rd-line: plan docetaxel</p>	<p>1st-line: iUPD of lymph nodes and bone metastasis by PET-CT after cycle 4; PR by PET-CT after cycle 6; PD of lymph nodes and bone metastases by PET-CT after cycle 9</p> <p>2nd-line: PD of bone metastases by PET-CT after cycle 4</p>
Case 2	79/Male	Non-smoker	Nil	Adenosquamous carcinoma	<p>1. Tissue conventional PCR at diagnosis: EGFR L858R</p> <p>2. Liquid NGS on progression: EGFR L858R and TP53</p>	<p>1st-line: EGFR TKIs for 4 months</p> <p>2nd-line: paclitaxel/carboplatin for one cycle</p> <p>3rd-line: osimertinib/tepotinib for 3 months</p> <p>4th-line: T-DXd for two cycles</p>	<p>1st-line: initial response with decrease in CEA level, followed by mixed response in the liver and bone with new emerging metastases by PET-CT</p>

Age/Sex	Smoking status	Medical history	Histology	Molecular test result	Summary of systemic treatment	Outcome
				3. Tissue conventional PCR on progression: EGFR L858R 4. Tissue NGS on progression: EGFR L858R, <i>MET</i> amplification and ERBB2 S310Y		after 4 months of EGFR TKIs 2nd-line: poor tolerance 3rd-line: initial decrease in CEA level, followed by a rebound and PD of lung, pleural, liver and bone metastases by PET-CT after 3 months of dual EGFR-MET TKIs 4th-line: CEA level downtrends but PD of liver metastasis by PET-CT after cycle 2 Patient deceased

Abbreviations: CEA = carcinoembryonic antigen; CT = computed tomography; EGFR = epidermal growth factor receptor; iUPD = immune unconfirmed progressive disease; NGS = next-generation sequencing; PCR = polymerase chain reaction; PD = progressive disease; PET = positron emission tomography; PR = partial response; SBRT = stereotactic body radiation therapy; T-DXd = trastuzumab deruxtecan; TKI = tyrosine kinase inhibitor.